Clinical Trial

Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC

Name: Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC — clinical trial record (NCT07724886)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.

Trial Details

NCT Number	NCT07724886
Lead Sponsor	Chinese University of Hong Kong
Conditions	Bladder Cancer
Enrollment	732 participants
Start Date	2026-07-01
Primary Completion	2029-12-31 (estimated)
Study Completion	2030-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-03